Skip to content

Endoscopic Resection of Non-ampullary Duodenal Adenomas: Endoscopic Mucosal Resection (EMR) vs. Endoscopic Full-thickness Resection With the 'Duodenal Full-thickness Resection Device' (dFTRD)

Endoscopic Resection of Non-ampullary Duodenal Adenomas: Endoscopic Mucosal Resection (EMR) vs. Endoscopic Full-thickness Resection With the 'Duodenal Full-thickness Resection Device' (dFTRD)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03559231
Acronym
DUO-RESECT
Enrollment
100
Registered
2018-06-18
Start date
2018-05-12
Completion date
2021-05-12
Last updated
2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duodenal Adenoma

Keywords

duodenal adenoma, FTRD, dFTRD, EMR, endoscopic mucosal resection

Brief summary

Prospective, randomized multi-center trial. Comparison of Endoscopic Mucosal Resection (EMR) versus Endoscopic Full-Thickness Resection with the duodenal Full-Thickness Resection Device (dFTRD) of non-ampullary duodenal adenomas.

Detailed description

Prospective, randomized multi-center trial. Comparison of Endoscopic Mucosal Resection (EMR) versus Endoscopic Full-Thickness Resection with the duodenal Full-Thickness Resection Device (dFTRD) of non-ampullary duodenal adenomas.

Interventions

PROCEDUREdFTRD

Duodenal Full-Thickness Resection

PROCEDUREEMR

Endoscopic Mucosal Resection

Sponsors

Kliniken Ludwigsburg-Bietigheim gGmbH
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* duodenal adenoma * age 18 or older * written informed consent

Exclusion criteria

* duodenal adenomas with a size \> 25 mm * duodenal adenomas with 20 mm or less distance to the major and/or minor duodenal papilla * presence of two or more duodenal adenomas * suspected or histologically confirmed malignancy * tumor disease (exception: after successful curative treatment) * conditions/diseases of the upper GI-tract that impair advancing of the devices into the duodenum * moribund patient * pregnancy and breastfeeding * patients that cannot give informed consent (e.g. psychiatric disorders, language barrier,...) * other contraindications for duodenal resections

Design outcomes

Primary

MeasureTime frameDescription
Complication Rate30 daysComposite endpoint of perforations and relevant bleeding

Secondary

MeasureTime frameDescription
'R0'-Resectionwithin one week after resection (as soon as result of pathologic analysis of resected specimen is available)Rate of microscopic complete resections
Rate of 'en bloc' resectionswithin one week after resection (as soon as result of pathologic analysis of resected specimen is available)Rate of 'en bloc' resections
Need of secondary surgical intervention3 months
Procedure time30 daystime span of the procedure according to sedation protocol
Technical successintraoperativeRate of macroscopic complete resections
number of patients with residual or recurrent duodenal adenoma at the follow-up endoscopy after 3 months3 months
number of patients with residual or recurrent duodenal adenoma at the follow-up endoscopy after 1 year1 year
number of necessary re-endoscopies3 months
Duration of hospitalization30 days

Countries

Germany

Contacts

Primary ContactMarkus Bauder, MD
markus.bauder@kliniken-lb.de+49(0)7141-99-67201
Backup ContactKarel Caca, MD, PhD
karel.caca@kliniken-lb.de+49(0)7141-99-67201

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026